Incannex is a clinical stage pharmaceutical development company that is developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications.
Company profile
Ticker
IXHL, IHLXF
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Incannex Healthcare Ltd
SEC CIK
Latest filings (excl ownership)
8-K
Other Events
30 May 24
10-Q
2024 Q3
Quarterly report
15 May 24
8-K
Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder
7 May 24
8-K
Incannex Healthcare Inc. Quarterly Update, Q1 2024
16 Apr 24
8-K
Departure of Directors or Certain Officers
5 Mar 24
8-K
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder
28 Feb 24
8-K
Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation
16 Feb 24
10-Q
2024 Q2
Quarterly report
14 Feb 24
8-K
Other Events
1 Feb 24
8-K
Other Events
24 Jan 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Jun 23 | Jun 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 9.31 mm | 9.31 mm | 9.31 mm | 9.31 mm | 9.31 mm | 9.31 mm |
Cash burn (monthly) | 1.75 mm | 1.07 mm | 2.47 mm | 1.28 mm | 1.38 mm | 344.83 k |
Cash used (since last report) | 5.06 mm | 3.09 mm | 7.15 mm | 3.71 mm | 3.99 mm | 997.92 k |
Cash remaining | 4.24 mm | 6.21 mm | 2.15 mm | 5.59 mm | 5.31 mm | 8.31 mm |
Runway (months of cash) | 2.4 | 5.8 | 0.9 | 4.4 | 3.9 | 24.1 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
21 Dec 23 | Robert Clark | Common Stock | Grant | Acquire A | No | No | 0 | 100,000 | 0.00 | 100,000 |
21 Dec 23 | George Anastassov | Common Stock | Grant | Acquire A | No | No | 0 | 100,000 | 0.00 | 769,721 |
21 Dec 23 | Joel Latham | Common Stock | Grant | Acquire A | No | No | 0 | 1,340,000 | 0.00 | 1,577,485 |
21 Dec 23 | Peter Widdows | Common Stock | Grant | Acquire A | No | No | 0 | 100,000 | 0.00 | 270,847 |
21 Dec 23 | Troy Valentine | Common Stock | Grant | Acquire A | No | No | 0 | 670,000 | 0.00 | 699,250 |
Press releases
Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
30 May 24
Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder
7 May 24
Incannex Healthcare Inc. Quarterly Update, Q1 2024
16 Apr 24